Lytix Biopharma

Lytix Biopharma is a clinical-stage immunotherpy company developing a new class of oncolytic molecules designed to destroy tumors locally and elicit durable anti-tumor immunity. Our peptide-based oncolytic molecules, derived from host defense peptides, work through a dual mechanism: first, inducing rapid immunogenic tumor cell death that releases tumor antigens into the microenvironment; second, activating a lasting immune response that can prevent recurrence and improve responses to checkpoint inhibitors. Lytix is advancing ruxotemitide as a first-in-class oncolytic peptide for neoadjuvant melanoma, with broad potential across superficial tumors such as basal cell carcinoma and Merkel cell carcinoma. Our partner, Verrica Pharmaceuticals, has reported positive Phase 2 data in basal cell carcinoma, representing industrial validation of the platform. Our pipeline also includes LTX 401, targeting deep-seated tumors with strong preclinical data in liver cancer models. Lytix is positioned to deliver a new generation of immunotherapies that: • Are active against drug resistant cancer cells • Are efficacious, independent of tumor mutational burden and tumor heterogeneity • Elicit a broad T-cell response and infiltration into the tumor microenvironment • Work in synergy with immune checkpoint inhibitors through • Extend benefit to patients who have not responded to previous lines of immunotherapy • Are safely combinable with immune checkpoint inhibitors Headquartered in Oslo, Norway, Lytix Biopharma brings together a world-class advisory network, including Nobel Laureate Jim Allison, and global partners to accelerate the translation of our science into therapies that change the course of cancer treatment. We are building partnerships with pharmaceutical and biotech companies seeking to enhance immune response, improve clinical outcomes, and explore new frontiers in combination oncology.